Evidence map›Paper›PMID 35300346›Full record

ReviewJournal of oncology2022

Efficacy and Safety of Nanoadministration in the Treatment of Non-Small-Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta-Analysis.

Rui Han, Youhong Guan, Min Li, Aiqun Xu, Dong Wu, Pulin Li, Enze Wang, Peng Sun, Guanghe Fei, Sijing Zhou and 1 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Rui HanDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0002-7729-9165
Youhong GuanDepartment of Infectious Disease, Hefei Second People's Hospital, 230022 Hefei, China.ORCID https://orcid.org/0000-0002-0761-2005
Min LiDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0001-5112-5135
Aiqun XuDepartment of General Medicine, Hefei Second People's Hospital, Changjiang East Road, 230022 Hefei, China.ORCID https://orcid.org/0000-0002-6830-7952
Dong WuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0003-2399-1954
Pulin LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0002-3972-7413
Enze WangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0002-5755-5707
Peng SunDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0001-5154-8840
Guanghe FeiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0002-4120-606X
Sijing ZhouHefei Third Clinical College of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0002-1381-6397
Ran WangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.ORCID https://orcid.org/0000-0002-3016-1011
Anhui Medical University · CNHefei Infectious Disease Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The purpose of this study was to evaluate the efficacy and safety of a nanodrug delivery regimen compared with conventional drug administration for the treatment of lung cancer. Materials and Methods: Studies were retrieved through PubMed, Web of Science, and ScienceDirect. Primary and secondary outcome measures, including overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events, were extracted from the retrieved literature and systematically evaluated. Results: Six trials, including 4806 advanced non-small-cell lung cancer patients, were included in this study. Compared with conventional drug administration in the treatment of lung cancer, the nanodrug delivery regimen improved the ORR (risk ratio = 1.43, 95% confidence interval (CI) = 1.25-1.63, Conclusion: Nanodrug administration is safe and effective in patients with non-small-cell lung cancer to some extent.

Identifiers

PMID35300346
PMCPMC8923769
OpenAlexW4221022457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.